Litcius/Paper detail

OA05.04 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study

Byoung Chul Cho, M.C. Dols, Rubén Cabanillas, David Vicente Baz, J. Fuentes Pradera, Salvatore Grisanti, A.E. Gabayan, K.H. Lee, E.K. Cho, Sabeen Mekan, F. Safavi, N. Fernando, Michael Chisamore, Martin Reck

2023Journal of Thoracic Oncology13 citationsDOIOpen Access PDF

Topics & Concepts

PembrolizumabMedicineLung cancerOncologyMonoclonal antibodyInternal medicineFirst lineCancerImmunotherapyAntibodyImmunologyCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsImmunotherapy and Immune Responses
OA05.04 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non-Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study | Litcius